4-(4-cyclohexylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester | 926933-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-cyclohexylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester
• 英文别名: ethyl 4-(4-(cyclohexylmethyl)-4-hydroxypiperidin-1-yl)benzoate；ethyl 4-[4-(cyclohexylmethyl)-4-hydroxypiperidin-1-yl]benzoate
• CAS: 926933-59-7
• 化学式: C₂₁H₃₁NO₃
• 分子量: 345.482
• InChiKey: XZBMYWRSDKISOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-cyclohexylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester 在 4-二甲氨基吡啶 、 lithium hydroxide 、 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 14.0h， 生成 4-[4-(cyclohexylmethyl)-4-methoxypiperidin-1-yl]-N-[(4-{[(2R)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene)sulfonyl]benzamide
  参考文献：
  名称：

  Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL

  摘要：

  Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.

  DOI：

  10.1021/jm061152t
• 作为产物：
  描述：

  4-(4-氧代哌啶-1-基)苯甲酸乙酯 、 magnesium,methanidylcyclohexane,bromide 在 氯化铵 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 生成 4-(4-cyclohexylmethyl-4-hydroxy-piperidin-1-yl)-benzoic acid ethyl ester
  参考文献：
  名称：

  APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

  摘要：

  公开了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白疾病的方法。

  公开号：

  US20100184766A1

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Kunzer Aaron R.

  公开号：US20100184766A1

  公开（公告）日：2010-07-22

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  公开了抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及治疗表达抗凋亡Bcl-2蛋白疾病的方法。
• Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
  申请人：Abbott Laboratories

  公开号：US08338466B2

  公开（公告）日：2012-12-25

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  本发明涉及一些化合物，其抑制抗凋亡Bcl-2蛋白的活性，包含这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20160002187A1

  公开（公告）日：2016-01-07

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  公开了一种抑制抗凋亡Bcl-2蛋白活性的化合物，包含这些化合物的组合物以及用于治疗表达抗凋亡Bcl-2蛋白的疾病的方法。
• US8338466B2
  申请人：——

  公开号：US8338466B2

  公开（公告）日：2012-12-25
• US9156856B2
  申请人：——

  公开号：US9156856B2

  公开（公告）日：2015-10-13